Outset Medical, Inc. (OM)

SAN JOSE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the 23rd annual Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 7 a.m. Eastern time.

Outset Medical (OM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Outset Medical, Inc. (NASDAQ:OM ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants James S. Mazzola - Head of Investor Relations Leslie L.

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.76. This compares to a loss of $7.05 per share a year ago.

Company raises 2025 revenue guidance to a range of $122 million to $126 million Company raises 2025 revenue guidance to a range of $122 million to $126 million

SAN JOSE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced Brittni McGill has been named to the newly created role of Chief Nursing Officer where she will apply her extensive nurse executive leadership experience to help increase strategic outreach and clinical program innovation designed to empower nurses and nurse leaders and elevate care.

SAN JOSE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter 2025 after the close of trading on Wednesday, August 6, 2025.

The company's business model leverages recurring revenue streams and strong customer retention, supporting stable long-term growth. Key risks include potential regulatory changes and execution challenges that could impact future earnings. With FDA hurdles behind it and sales momentum building, Outset's Tablo is regaining traction across hospitals and ICU settings.

Outset Medical (OM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SAN JOSE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will present at the Goldman Sachs 46th annual Healthcare conference on Wednesday, June 11, 2025, at 11:20 a.m. Eastern time.

SAN JOSE, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective immediately. In addition to leading Finance, Ms. Gaeta will have responsibility for Outset's Information Technology and Human Resources organizations. She succeeds Nabeel Ahmed who is leaving the company to pursue other opportunities.

SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin O'Boyle to its Board of Directors and as chair of its Audit Committee. With Mr. O'Boyle's appointment, the company also announced that Dale E. Jones has stepped down from the Board.

SAN JOSE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate at the RBC Capital Markets Global Health Care conference on Tuesday, May 20, 2025, at 10:30 a.m. Eastern time.

Outset Medical, Inc. (OM) Q1 2025 Earnings Call Transcript

Outset Medical, Inc. (OM) came out with a quarterly loss of $3.24 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to loss of $8.55 per share a year ago.